The Impact of Tumor Hypoxia Modulation on SIL-2R Levels in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) Patients Undergoing Chemotherapy: A Randomized Clinical Trial

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2024 Apr 29

PMID 38679992

Authors

Daniel Rizky

Kevin Tandarto

Eko Adhi Pangarsa

Ridho M Naibaho

Sigit P Kurniawan

Damai Santosa

Budi Setiawan

Catharina Suharti

Affiliations

Soon will be listed here.

Abstract

Objective: Tumor hypoxia induces the production of Hypoxia-Inducible Factor (HIF)-1 alpha, which interacts with NF-kB, leading to cancer proliferation and metastasis. This study investigated the effect of tumor hypoxia modulation using carbogen (95% O2 and 5% CO2) and nicotinamide on reducing soluble interleukin-2 receptor (sIL-2R) levels in newly diagnosed DLBCL patients with tissue overexpression of HIF-1α ≥10%.

Material And Methods: A prospective randomized controlled clinical trial was conducted at Dr. Kariadi Hospital in Semarang, Indonesia, from 2021 to 2022. Newly diagnosed DLBCL patients with tissue HIF-1α ≥10% were randomized into an intervention group (nicotinamide 2,000 mg + carbogen 10 liters/min during R-CHOP) and a control group (R-CHOP alone) for one cycle. sIL-2R levels were measured in the blood before and after intervention.

Results: The intervention group showed a significant reduction in sIL-2R levels after chemotherapy (p=0.026), with 85% of samples exhibiting a decrease. In contrast, only 45% of samples in the control group demonstrated a decrease in sIL-2R levels (p=0.184). The median sIL-2R level decreased from 139.50 pg/mL to 70.50 pg/mL in the intervention group, while the control group exhibited an increase from 182.50 pg/mL to 250.00 pg/mL following one cycle of chemotherapy.

Conclusion: Tumor hypoxia modulation led to a significant decrease in serum sIL-2R levels, potentially through improvements in the crosstalk between hypoxia and inflammation pathways.

References

Vaupel P, Mayer A . Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007; 26(2):225-39. DOI: 10.1007/s10555-007-9055-1. View

DIgnazio L, Rocha S . Hypoxia Induced NF-κB. Cells. 2016; 5(1). PMC: 4810095. DOI: 10.3390/cells5010010. View

Scholz C, Cavadas M, Tambuwala M, Hams E, Rodriguez J, von Kriegsheim A . Regulation of IL-1β-induced NF-κB by hydroxylases links key hypoxic and inflammatory signaling pathways. Proc Natl Acad Sci U S A. 2013; 110(46):18490-5. PMC: 3832034. DOI: 10.1073/pnas.1309718110. View

Kusano Y, Yokoyama M, Terui Y, Inoue N, Takahashi A, Yamauchi H . High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy. Blood Cancer J. 2017; 7(9):e614. PMC: 5709758. DOI: 10.1038/bcj.2017.96. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Xie X, Xiao H, Ding F, Zhong H, Zhu J, Ma N . Over-expression of prolyl hydroxylase-1 blocks NF-κB-mediated cyclin D1 expression and proliferation in lung carcinoma cells. Cancer Genet. 2014; 207(5):188-94. DOI: 10.1016/j.cancergen.2014.04.008. View

Dhani N, Fyles A, Hedley D, Milosevic M . The clinical significance of hypoxia in human cancers. Semin Nucl Med. 2015; 45(2):110-21. DOI: 10.1053/j.semnuclmed.2014.11.002. View

Compagno M, Lim W, Grunn A, Nandula S, Brahmachary M, Shen Q . Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009; 459(7247):717-21. PMC: 2973325. DOI: 10.1038/nature07968. View

DIgnazio L, Bandarra D, Rocha S . NF-κB and HIF crosstalk in immune responses. FEBS J. 2015; 283(3):413-24. PMC: 4864946. DOI: 10.1111/febs.13578. View

10.

Hoskin P, Saunders M, Phillips H, Cladd H, Powell M, Goodchild K . Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy. Br J Cancer. 1997; 76(2):260-3. PMC: 2223941. DOI: 10.1038/bjc.1997.372. View

11.

Kennedy R, Klein U . Aberrant Activation of NF-κB Signalling in Aggressive Lymphoid Malignancies. Cells. 2018; 7(11). PMC: 6262606. DOI: 10.3390/cells7110189. View

12.

Hu Y, Bloy N, Elemento O, Buque A . Nicotinamide drives T cell activation in the mammary tumor microenvironment. J Transl Med. 2022; 20(1):251. PMC: 9164530. DOI: 10.1186/s12967-022-03454-z. View

13.

Oki Y, Kato H, Matsuo K, Kuwatsuka Y, Taji H, Yamamoto K . Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy. Leuk Lymphoma. 2008; 49(7):1345-51. DOI: 10.1080/10428190802108888. View

14.

Demchenko Y, Kuehl W . A critical role for the NFkB pathway in multiple myeloma. Oncotarget. 2010; 1(1):59-68. PMC: 2947827. DOI: 10.18632/oncotarget.109. View

15.

Sahu A, Kwon I, Tae G . Improving cancer therapy through the nanomaterials-assisted alleviation of hypoxia. Biomaterials. 2019; 228:119578. DOI: 10.1016/j.biomaterials.2019.119578. View

16.

Yoshida N, Oda M, Kuroda Y, Katayama Y, Okikawa Y, Masunari T . Clinical significance of sIL-2R levels in B-cell lymphomas. PLoS One. 2013; 8(11):e78730. PMC: 3827264. DOI: 10.1371/journal.pone.0078730. View

17.

Moynagh P . The NF-kappaB pathway. J Cell Sci. 2005; 118(Pt 20):4589-92. DOI: 10.1242/jcs.02579. View

18.

Cummins E, Berra E, Comerford K, Ginouves A, Fitzgerald K, Seeballuck F . Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci U S A. 2006; 103(48):18154-9. PMC: 1643842. DOI: 10.1073/pnas.0602235103. View

19.

Brizel D, Lin S, Johnson J, Brooks J, Dewhirst M, Piantadosi C . The mechanisms by which hyperbaric oxygen and carbogen improve tumour oxygenation. Br J Cancer. 1995; 72(5):1120-4. PMC: 2033965. DOI: 10.1038/bjc.1995.474. View

20.

Murakami J, Arita K, Wada A, Mihara H, Origasa H, Kigawa M . Serum soluble interleukin-2 receptor levels for screening for malignant lymphomas and differential diagnosis from other conditions. Mol Clin Oncol. 2019; 11(5):474-482. PMC: 6787963. DOI: 10.3892/mco.2019.1922. View